<DOC>
	<DOCNO>NCT01286779</DOCNO>
	<brief_summary>The purpose BAX 326 Continuation Study investigate incremental recovery time , hemostatic efficacy , safety , immunogenicity , health-related quality life ( HR QoL ) BAX 326 previously treat patient ( PTPs ) severe moderately severe hemophilia B participate BAX 326 pivotal study 250901 BAX 326 pediatric study 251101 .</brief_summary>
	<brief_title>BAX 326 ( rFIX ) Continuation Study</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<criteria>Main Subject and/or legal representative has/have voluntarily provide sign informed consent Subject complete Baxter clinical study 250901 ( pivotal study ) Baxter clinical study 251101 ( pediatric study ) Subject 12 65 year old time screen Study 250901 &lt; 12 year old time screen Study 251101 Subject severe ( FIX level &lt; 1 % ) moderately severe ( FIX level 12 % ) hemophilia B ( base one stage activate partial thromboplastin time ( aPTT ) assay ) , test screening central laboratory Subject develop inhibitory FIX antibody Baxter Pivotal Study 250901 Pediatric Study 251101 Main Subject receive factor IX product ( ) BAX 326 upon completion Baxter Pivotal Study 250901 Pediatric Study 251101 Subject diagnose acquire hemostatic defect hemophilia B For subject transfer Pivotal Study 250901 : Subject 's weight &lt; 35 kg &gt; 120 kg Subject plan take part clinical study , exception BAX 326 Surgery study describe protocol , course Continuation Study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>